» Articles » PMID: 24255689

Peptide Nucleic Acid Clamp Polymerase Chain Reaction Reveals a Deletion Mutation of the Gene in Papillary Thyroid Carcinoma: A Case Report

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2013 Nov 21
PMID 24255689
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The point mutation is the most common genetic event in papillary thyroid carcinoma (PTC), occurring in 29-69% of such tumors. The V600E mutation accounts for up to 95% of all mutations. Therefore, the majority of diagnostic assays have been developed to detect only the V600E mutation of the gene. A peptide nucleic-acid (PNA)-clamp quantitative polymerase chain reaction (qPCR) was developed to detect the V600E mutation and other mutations in the gene. In this study, a 3-bp deletion mutation (c.1799_ 1801delTGA) was detected in a subject with a PTC by PNA clamp qPCR, in contrast with the results of allele-specific (AS)-PCR. The mutant allele was not detected by AS-PCR, but was detected using PNA-clamp PCR. The atypical 3-bp deletion mutation (c.1799_1801delTGA) was identified by confirmatory PCR combined with sequencing. The conversion of codons 600 (GTG) and 601 (AAA) into a single codon (GAA) resulted in the insertion of a glutamic acid residue into the activation segment of the B-raf protein (p.V600_K601delinsE). In cases where PTC is highly suspected but no mutation is detected by AS-PCR specific for V600E, PNA clamp qPCR, which is complementary to other sequencing methods, should be performed in order to detect other mutations in the gene.

Citing Articles

Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report.

Lee P, Chen J, Pan L, Hwu C, Hang J, Kuo C Medicine (Baltimore). 2024; 103(34):e39364.

PMID: 39288226 PMC: 11346887. DOI: 10.1097/MD.0000000000039364.


Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S Clin Cancer Res. 2018; 24(13):3059-3068.

PMID: 29615459 PMC: 6030480. DOI: 10.1158/1078-0432.CCR-18-0373.


(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

Schneider T, Kapiteijn E, van Wezel T, Smit J, van der Hoeven J, Morreau H BMC Cancer. 2016; 16:31.

PMID: 26786320 PMC: 4719736. DOI: 10.1186/s12885-016-2060-4.


A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Martinuzzi C, Pastorino L, Andreotti V, Garuti A, Minuto M, Fiocca R Endocrine. 2015; 53(3):672-80.

PMID: 26296380 DOI: 10.1007/s12020-015-0720-9.


A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma.

Dvorakova S, Sykorova V, Vaclavikova E, Sykorova P, Vlcek P, Kodetova D Endocr Pathol. 2015; 26(4):309-14.

PMID: 26231782 DOI: 10.1007/s12022-015-9387-2.

References
1.
Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

2.
Kim S, Kim D, Han H, Kim W, Kim S, Moon W . Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol. 2008; 17(2):118-25. DOI: 10.1097/PDM.0b013e31815d059d. View

3.
Park S, Park Y, Lee Y, Lee H, Choi S, Choe G . Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer. 2006; 107(8):1831-8. DOI: 10.1002/cncr.22218. View

4.
Chung K, Yang S, Lee G, Kim E, Kwon S, Lee S . Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006; 65(5):660-6. DOI: 10.1111/j.1365-2265.2006.02646.x. View

5.
Trovisco V, Soares P, Soares R, Magalhaes J, Sa-Couto P, Sobrinho-Simoes M . A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005; 36(6):694-7. DOI: 10.1016/j.humpath.2005.04.011. View